Go Pro
NASDAQ:TWST

Twist Bioscience (TWST) Stock Price, News & Analysis

Twist Bioscience logo
$159.00 -5.60 (-3.40%)
As of 01:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Twist Bioscience Stock (NASDAQ:TWST)

Advanced

Key Stats

Today's Range
$157.41
$166.35
50-Day Range
$85.47
$166.99
52-Week Range
$23.30
$170.66
Volume
1.19 million shs
Average Volume
1.56 million shs
Market Capitalization
$9.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$103.00
Consensus Rating
Moderate Buy

Company Overview

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California. The company serves customers internationally through its products, services and commercial operations. Emily M. Leproust, a co-founder of Twist Bioscience, has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

Twist Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

TWST MarketRank™: 

Twist Bioscience scored higher than 34% of companies evaluated by MarketBeat, and ranked 674th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Twist Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 2 sell ratings.

  • Downside Risk

    Twist Bioscience has a consensus price target of $103.00, representing about 36.8% downside from its current price of $163.06.

  • Amount of Analyst Coverage

    Twist Bioscience has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Twist Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Twist Bioscience are expected to grow in the coming year, from ($2.12) to ($1.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Twist Bioscience is -73.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Twist Bioscience is -73.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Twist Bioscience has a P/B Ratio of 20.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Twist Bioscience's valuation and earnings.
  • Percentage of Shares Shorted

    19.85% of the float of Twist Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Twist Bioscience has a short interest ratio ("days to cover") of 6.91.
  • Change versus previous month

    Short interest in Twist Bioscience has recently decreased by 14.49%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Twist Bioscience does not currently pay a dividend.

  • Dividend Growth

    Twist Bioscience does not have a long track record of dividend growth.

  • News Sentiment

    Twist Bioscience has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Twist Bioscience this week, compared to 6 articles on an average week.
  • Search Interest

    Only 9 people have searched for TWST on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Twist Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $80,176,708.00 in company stock.

  • Percentage Held by Insiders

    3.08% of the stock of Twist Bioscience is held by insiders.

  • Percentage Held by Institutions

    Twist Bioscience has minimal institutional ownership at this time.

  • Read more about Twist Bioscience's insider trading history.
Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TWST Stock News Headlines

Twist Bioscience (NASDAQ:TWST) Hits New 12-Month High - Here's Why
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
3 Analysts, 3 Trades to Make Today
See More Headlines

TWST Stock Analysis - Frequently Asked Questions

Twist Bioscience's stock was trading at $31.72 at the start of the year. Since then, TWST shares have increased by 414.1% and is now trading at $163.06.

Twist Bioscience Corporation (NASDAQ:TWST) posted its quarterly earnings results on Monday, August, 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.05. Twist Bioscience's revenue was up 23.2% compared to the same quarter last year.
Read the conference call transcript
.

Twist Bioscience (TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience's top institutional investors include BlackRock Inc. (9.30%), William Blair Investment Management LLC (3.47%), Bank of America Corp DE (1.47%) and First Light Asset Management LLC (1.16%). Insiders that own company stock include Emily M Leproust, William Banyai, Patrick John Finn, Paula Green, Adam Laponis, Dennis Cho, Robert F Werner, Melissa A Starovasnik, Robert Chess and Jan Johannessen.
View institutional ownership trends
.

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Twist Bioscience investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/03/2026
Today
9/23/2026
Fiscal Year End
9/30/2026
Next Earnings (Estimated)
11/13/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TWST
CIK
1581280
Fax
N/A
Employees
979
Year Founded
2013

Price Target and Rating

High Price Target
$160.00
Low Price Target
$41.00
Potential Upside/Downside
-35.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.67 million
Net Margins
-31.66%
Pretax Margin
-31.46%
Return on Equity
-28.64%
Return on Assets
-19.94%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
2.67
Quick Ratio
2.38

Sales & Book Value

Annual Sales
$376.57 million
Price / Sales
26.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.84 per share
Price / Book
20.34

Miscellaneous

Outstanding Shares
62,710,000
Free Float
60,776,000
Market Cap
$10.00 billion
Optionable
Optionable
Beta
2.22

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:TWST) was last updated on 9/23/2026 by MarketBeat.com Staff.
From Our Partners